Markus Munder

9.3k total citations · 4 hit papers
80 papers, 6.1k citations indexed

About

Markus Munder is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Markus Munder has authored 80 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 24 papers in Hematology and 18 papers in Oncology. Recurrent topics in Markus Munder's work include Multiple Myeloma Research and Treatments (22 papers), Immune Cell Function and Interaction (16 papers) and Immune cells in cancer (15 papers). Markus Munder is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Immune Cell Function and Interaction (16 papers) and Immune cells in cancer (15 papers). Markus Munder collaborates with scholars based in Germany, United Kingdom and United States. Markus Munder's co-authors include Manuel Modolell, Klaus Eichmann, Pascale Kropf, Ellen I. Closs, Meera Rath, Ingrid Müller, Moisés Mallo, Germán Soler, Francisco Centeno and José M. Morán and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Markus Munder

77 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages

2014 947 citations Pascale Kropf, Ellen I. Closs et al. Frontiers in Immunology profile →
Arginase: an emerging key player in the mammalian immune system

2009 538 citations Markus Munder British Journal of Pharmacology profile →
Murine Macrophages Secrete Interferon γ upon Combined Stimulation with Interleukin (IL)-12 and IL-18: A Novel Pathway of Autocrine Macrophage Activation

1998 506 citations Markus Munder, Manuel Modolell et al. profile →
Alternative Metabolic States in Murine Macrophages Reflected by the Nitric Oxide Synthase/Arginase Balance: Competitive Regulation by CD4+ T Cells Correlates with Th1/Th2 Phenotype

1998 500 citations Markus Munder, Manuel Modolell et al. The Journal of Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus Munder Germany	35	3.3k	1.5k	933	767	652	80	6.1k
Heinrich Körner Australia	47	4.2k 1.3×	1.7k 1.1×	1.2k 1.2×	1.3k 1.7×	725 1.1×	128	7.8k
Amit Awasthi India	33	6.1k 1.8×	1.2k 0.8×	801 0.9×	1.3k 1.6×	611 0.9×	99	8.4k
Christoph Mueller Switzerland	49	3.6k 1.1×	1.8k 1.2×	882 0.9×	1.1k 1.5×	294 0.5×	145	6.9k
Irina A. Udalova United Kingdom	43	3.9k 1.2×	1.9k 1.3×	1.0k 1.1×	864 1.1×	281 0.4×	93	6.8k
Anthony Rongvaux United States	32	3.2k 0.9×	2.7k 1.8×	925 1.0×	1.2k 1.6×	252 0.4×	51	6.5k
Damo Xu United Kingdom	28	3.9k 1.2×	1.1k 0.7×	977 1.0×	393 0.5×	778 1.2×	35	6.0k
Tanya N. Mayadas United States	52	4.6k 1.4×	2.2k 1.4×	848 0.9×	579 0.8×	339 0.5×	80	8.9k
Shruti Sharma United States	36	3.0k 0.9×	3.0k 2.0×	778 0.8×	539 0.7×	408 0.6×	140	6.3k
Jack B. Cowland Denmark	40	3.1k 0.9×	2.4k 1.6×	782 0.8×	488 0.6×	476 0.7×	80	7.5k
Stephen T. Smiley United States	35	4.3k 1.3×	1.6k 1.0×	732 0.8×	1.6k 2.0×	360 0.6×	64	7.4k

Countries citing papers authored by Markus Munder

Since Specialization

Citations

This map shows the geographic impact of Markus Munder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Munder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Munder more than expected).

Fields of papers citing papers by Markus Munder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Munder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Munder. The network helps show where Markus Munder may publish in the future.

Co-authorship network of co-authors of Markus Munder

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Munder. A scholar is included among the top collaborators of Markus Munder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Munder. Markus Munder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garderet, Laurent, Joanna Wasielica‐Poslednik, Markus Munder, et al.. (2021). Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. Leukemia & lymphoma. 63(4). 984–990. 3 indexed citations

Boulos, Joelle C., Mohamed E.M. Saeed, Manik Chatterjee, et al.. (2021). Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells. Pharmaceuticals. 14(11). 1126–1126. 19 indexed citations

Garderet, Laurent, Joanna Wasielica‐Poslednik, Markus Munder, et al.. (2021). Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes. Blood. 138(Supplement 1). 2695–2695. 1 indexed citations

Kadioglu, Onat, et al.. (2020). Effect of ABC transporter expression and mutational status on survival rates of cancer patients. Biomedicine & Pharmacotherapy. 131. 110718–110718. 39 indexed citations

Gerlach, Christina, Kathy Taylor, Marion Ferner, et al.. (2020). Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer. 20(1). 245–245. 6 indexed citations

Werner, Anke, Hakim Echchannaoui, Johanna Rupp, et al.. (2019). Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. Frontiers in Oncology. 9. 1268–1268. 36 indexed citations

Kriegsmann, Katharina, Jens Hillengaß, Marc S. Raab, et al.. (2018). The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. OncoImmunology. 7(10). e1486356–e1486356. 15 indexed citations

Lentzsch, Suzanne, Katja Weisel, MV Mateos, et al.. (2017). DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR). Hematological Oncology. 35(S2). 388–389. 5 indexed citations

Yizengaw, Endalew, Emebet Adem, Asrat Hailu, et al.. (2016). Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions. Frontiers in Immunology. 7. 517–517. 33 indexed citations

10.

Adem, Emebet, Ermias Diro, Asrat Hailu, et al.. (2016). Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production. PLoS neglected tropical diseases. 10(3). e0004468–e0004468. 22 indexed citations

11.

Merz, Maximilian, Mathias Haenel, Uta Bertsch, et al.. (2015). Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. Blood. 126(23). 4233–4233. 2 indexed citations

12.

Takele, Yegnasew, Tamrat Abebe, Teklu Weldegebreal, et al.. (2013). Correction: Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection. PLoS neglected tropical diseases. 7(1). 5 indexed citations

13.

García‐Navas, Rósula, Markus Munder, & Faustino Mollinedo. (2012). Depletion ofL-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes. Autophagy. 8(11). 1557–1576. 72 indexed citations

14.

Nicholson, Lindsay, Ben J. E. Raveney, & Markus Munder. (2009). Monocyte Dependent Regulation of Autoimmune Inflammation. Current Molecular Medicine. 9(1). 23–29. 53 indexed citations

15.

Watzl, Carsten, Thomas Giese, Pascale Kropf, et al.. (2009). Regulation of NK Cell Function by Human Granulocyte Arginase. The Journal of Immunology. 182(9). 5259–5267. 112 indexed citations

16.

Munder, Markus, Beak‐San Choi, Matthew E. Rogers, & Pascale Kropf. (2009). L‐Arginine deprivation impairs Leishmania major‐specific T‐cell responses. European Journal of Immunology. 39(8). 2161–2172. 60 indexed citations

17.

Munder, Markus. (2009). Role of arginase in asthma: potential clinical applications. Expert Review of Clinical Pharmacology. 3(1). 17–23. 8 indexed citations

18.

Munder, Markus. (2009). Arginase: an emerging key player in the mammalian immune system. British Journal of Pharmacology. 158(3). 638–651. 538 indexed citations breakdown →

19.

Munder, Markus. (2004). Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood. 105(6). 2549–2556. 264 indexed citations

20.

Munder, Markus, et al.. (1995). Identification of the porcine intestinal accessory factor that enables DNA sequence recognition by vitamin D receptor.. Proceedings of the National Academy of Sciences. 92(7). 2795–2799. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact